222 related articles for article (PubMed ID: 31195686)
21. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
22. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
23. CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A; Krahl AC; André MC; Hombach AA; Abken H
Hum Gene Ther; 2017 Dec; 28(12):1147-1157. PubMed ID: 29207878
[TBL] [Abstract][Full Text] [Related]
24. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia.
van Wering ER; Beishuizen A; Roeffen ET; van der Linden-Schrever BE; Verhoeven MA; Hählen K; Hooijkaas H; van Dongen JJ
Leukemia; 1995 Sep; 9(9):1523-33. PubMed ID: 7658722
[TBL] [Abstract][Full Text] [Related]
26. Photothermal Therapy Promotes Tumor Infiltration and Antitumor Activity of CAR T Cells.
Chen Q; Hu Q; Dukhovlinova E; Chen G; Ahn S; Wang C; Ogunnaike EA; Ligler FS; Dotti G; Gu Z
Adv Mater; 2019 Jun; 31(23):e1900192. PubMed ID: 30916367
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
28. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
29. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
Front Oncol; 2022; 12():939166. PubMed ID: 36110930
[TBL] [Abstract][Full Text] [Related]
30. Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.
Bouhassira DC; Thompson JJ; Davila ML
Expert Opin Biol Ther; 2015 Mar; 15(3):403-16. PubMed ID: 25666545
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
32. Mixed phenotype acute leukemia with t(11;19)(q23;p13.3)/ MLL-MLLT1(ENL), B/T-lymphoid type: A first case report.
Naghashpour M; Lancet J; Moscinski L; Zhang L
Am J Hematol; 2010 Jun; 85(6):451-4. PubMed ID: 20513125
[TBL] [Abstract][Full Text] [Related]
33. [Adoptive immunotherapy utilizing anti-CD19 chimeric antigen receptor T-cells for B-cell malignancies].
Oh I; Oh Y; Ohmine K
Rinsho Ketsueki; 2016; 57(11):2365-2372. PubMed ID: 27941287
[TBL] [Abstract][Full Text] [Related]
34. Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.
Kropp KN; Fatho M; Huduti E; Faust M; Lübcke S; Lennerz V; Paschen A; Theobald M; Wölfel T; Wölfel C
Front Immunol; 2023; 14():1245559. PubMed ID: 37849763
[TBL] [Abstract][Full Text] [Related]
35. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
36. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor.
Laurin D; Marin V; Biagi E; Pizzitola I; Agostoni V; Gallot G; Vié H; Jacob MC; Chaperot L; Aspord C; Plumas J
J Immunother; 2013 Apr; 36(3):181-9. PubMed ID: 23502765
[TBL] [Abstract][Full Text] [Related]
38. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
Kurokawa T; Imai K
Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
